Statin use vs. average non-HDL cholesterol levels in Cyprus

Cyprus: Statin use vs. average non-HDL cholesterol levels was 3.5 in 2018. ▼ Falling

Latest (2018)
3.5
Change on year
down 2.8%
World rank
52nd
of 191 countries
All-time high
4.2
in 1980
All-time low
3.5
in 2018
Years of data
39
1980–2018

Statin use vs. average non-HDL cholesterol levels in Cyprus, 1980–2018

012341980199920181980: 4.21981: 4.21982: 4.21983: 4.21984: 4.21985: 4.21986: 4.21987: 4.21988: 4.21989: 4.21990: 4.11991: 4.11992: 4.11993: 4.11994: 4.11995: 41996: 41997: 41998: 41999: 3.92000: 3.92001: 3.92002: 3.82003: 3.82004: 3.82005: 3.82006: 3.82007: 3.72008: 3.72009: 3.72010: 3.72011: 3.72012: 3.72013: 3.62014: 3.62015: 3.62016: 3.62017: 3.62018: 3.5

Source: World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.

Analysis

In 2018, statin use vs. average non-hdl cholesterol levels in Cyprus stood at 3.5. That is the lowest value across all 39 years on record.

That represents a change of down 2.8% on the previous year and down 5.4% over ten years.

Over the whole period, statin use vs. average non-hdl cholesterol levels in Cyprus peaked at 4.2 in 1980 and was at its lowest, 3.5, in 2018.

That places Cyprus 52nd out of 191 countries with data for 2018, putting it in the middle of the range.

The long-run direction has been consistently falling across the 39 years of available data.

Averages by decade

DecadeAverage LowestHighest Years
1980s 4.2 4.2 4.2 10
1990s 4.04 3.9 4.1 10
2000s 3.79 3.7 3.9 10
2010s 3.62 3.5 3.7 9

Countries ranked near Cyprus

  1. 52 Antigua and Barbuda 3.5 compare
  2. 52 Bahamas 3.5 compare
  3. 52 Czechia 3.5 compare
  4. 52 Dominica 3.5 compare
  5. 52 El Salvador 3.5 compare
  6. 52 Finland 3.5 compare
  7. 52 Greece 3.5 compare
  8. 52 Grenada 3.5 compare
  9. 52 Guatemala 3.5 compare
  10. 52 Haiti 3.5 compare
  11. 52 Iraq 3.5 compare
  12. 52 Italy 3.5 compare
  13. 52 Maldives 3.5 compare
  14. 52 Micronesia (country) 3.5 compare
  15. 52 Norway 3.5 compare
  16. 52 Paraguay 3.5 compare
  17. 52 Poland 3.5 compare
  18. 52 Saint Kitts and Nevis 3.5 compare
  19. 52 Saint Lucia 3.5 compare
  20. 52 Trinidad and Tobago 3.5 compare
  21. 52 United Arab Emirates 3.5 compare
  22. 52 Vietnam 3.5 compare

See the full ranking of 191 places →

More reference data data for Cyprus

All data for Cyprus →

Frequently asked questions

What is statin use vs. average non-hdl cholesterol levels in Cyprus?
Statin use vs. average non-hdl cholesterol levels in Cyprus was 3.5 in 2018, according to World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.
What is the highest statin use vs. average non-hdl cholesterol levels recorded in Cyprus?
The highest recorded value was 4.2 in 1980.
What is the lowest statin use vs. average non-hdl cholesterol levels recorded in Cyprus?
The lowest recorded value was 3.5 in 2018.
How does Cyprus rank for statin use vs. average non-hdl cholesterol levels?
Cyprus ranks 52nd out of 191 countries with data for 2018.
Is statin use vs. average non-hdl cholesterol levels rising or falling in Cyprus?
Over the last ten years it is down 5.4%. The long-run trend across the full record is falling.
Where does this Cyprus data come from?
The figures come from World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as part of Statin use vs. average non-HDL cholesterol levels. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 39 observations, free to reuse under CC BY 4.0 (Our World in Data).

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.